A study that found benefits in metabolic syndrome patients given Sabinsa Corporation’s Curcumin C3 Complex® was chosen by a panel of experts for the NutraIngredients University Research of the Year Award, announced last week in Geneva, Switzerland. This award, given to research that “takes the nutrition sector to a new level of understanding, with clear potential for the development of market changing products,” honored the study conducted at Mashhad University of Medical Sciences on C3 Complex and metabolic syndrome.
This study investigates the safety and efficacy of Curcumin C3 Complex® in management of serum lipid concentrations in metabolic syndrome patients. The study results showed that Curcumin C3 Complex® plus BioPerine® combination was well tolerated and also improved the serum lipid health in metabolic syndrome patients. (Panahi Y, Khalili N, Hosseini MS, Abbasinazari M, Sahebkar A. Lipid-modifying effects of adjunctive therapy with curcumioids-piperine combination in patients with metabolic syndrome: Results of a randomized controlled trial. Complementary Therapies in Medicine ; 2014; 22(5): 851-57).
“Curcumin C3 Complex® is the most studied Curcumin ingredient on the market, primarily for inflammation, but this study is particularly significant in that it investigates another condition that has serious health implications in a large percentage of the population,” said Sabinsa founder Dr. Muhammed Majeed. “We thank NutraIngredients and their panel of experts for acknowledging the significance of this research and we thank the researchers for carrying out this important new study.”
Eight-week supplementation with Curcumin C3 Complex® and BioPerine was associated with a reduction of serum triglycerides, total cholesterol, serum low density lipoprotein-cholesterol, non-high density lipoprotein cholesterol, lipoprotein (a) and increase in the high density lipoprotein cholesterol (HDL) as compared to placebo.